LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Becton Dickinson and Co

Closed

SectorHealthcare

170.79 0.55

Overview

Share price change

24h

Current

Min

168.92

Max

172.19

Key metrics

By Trading Economics

Income

27M

330M

Sales

104M

5.3B

P/E

Sector Avg

32.892

50.291

EPS

3.35

Dividend yield

2.45

Profit margin

6.259

Employees

70,000

EBITDA

93M

546M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+18.08% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

2.45%

2.40%

Next Earnings

7 sie 2025

Next Dividend date

30 cze 2025

Next Ex Dividend date

8 wrz 2025

Market Stats

By TradingEconomics

Market Cap

-17B

49B

Previous open

170.24

Previous close

170.79

News Sentiment

By Acuity

33%

67%

91 / 380 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Becton Dickinson and Co Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

1 maj 2025, 11:18 UTC

Earnings

Becton 2Q Net Down, Warns of Tariff Hit on 2025 EPS

5 lut 2025, 22:09 UTC

Acquisitions, Mergers, Takeovers

Becton Dickinson to Separate From Bioscience and Diagnostic Solutions Business

7 lis 2024, 12:59 UTC

Earnings

Becton Dickinson Profit Rises as Acquisition Buoys Sales - Update

7 lis 2024, 12:56 UTC

Earnings

Becton Dickinson Fiscal 4Q Profit Rises as Acquisition Buoys Sales

1 maj 2025, 10:33 UTC

Earnings

Becton Dickinson Cuts FY25 Adj EPS View on Tariff Impact

1 maj 2025, 10:33 UTC

Earnings

Becton Dickinson FY25 Adj EPS View Includes an Estimated Tariff Impact of Approximately 25c

1 maj 2025, 10:32 UTC

Earnings

Becton Dickinson Sees FY25 Organic Rev Growth Guidance of 3.0% to 3.5% >BDX

1 maj 2025, 10:32 UTC

Earnings

Becton Dickinson Narrows FY25 View To Rev $21.8B-$21.9B >BDX

1 maj 2025, 10:31 UTC

Earnings

Becton Dickinson Intends To Invest $2.5 B in U.S. Manufacturing Capacity Over the Next 5 Years >BDX

1 maj 2025, 10:31 UTC

Earnings

Becton Dickinson: Taking 'Decisive Mitigation Actions to Navigate the Current Macro Environment' >BDX

1 maj 2025, 10:30 UTC

Earnings

Becton Dickinson Updates full-Yr Fiscal 2025 Guidance and Provides Estimated Tariff Impact >BDX

1 maj 2025, 10:30 UTC

Earnings

Becton Dickinson Sees FY Adj EPS $14.06-Adj EPS $14.34 >BDX

1 maj 2025, 10:30 UTC

Earnings

Becton Dickinson 2Q Net $308M >BDX

1 maj 2025, 10:30 UTC

Earnings

Becton Dickinson 2Q EPS $1.07 >BDX

1 maj 2025, 10:30 UTC

Earnings

Becton Dickinson 2Q Adj EPS $3.35 >BDX

1 maj 2025, 10:30 UTC

Earnings

Becton Dickinson 2Q Rev $5.3B >BDX

5 lut 2025, 21:56 UTC

Earnings

Correct: Becton Dickinson Sees 2025 Adj EPS $14.30-Adj EPS $14.60 >BDX

5 lut 2025, 21:54 UTC

Earnings

Becton Dickinson Sees 2025 EPS $14.30-EPS $14.60 >BDX

5 lut 2025, 21:54 UTC

Earnings

Becton Dickinson Sees 2025 GAAP Rev Growth 7.9% to 8.4% >BDX

5 lut 2025, 21:53 UTC

Earnings

Becton Dickinson Sees 2025 Rev $21.7B-$21.9B >BDX

5 lut 2025, 21:30 UTC

Earnings

Becton Dickinson 1Q Adj EPS $3.43 >BDX

5 lut 2025, 21:30 UTC

Earnings

Becton Dickinson 1Q Rev $5.2B >BDX

5 lut 2025, 21:30 UTC

Earnings

Becton Dickinson 1Q Net $303M >BDX

5 lut 2025, 21:30 UTC

Earnings

Becton Dickinson 1Q EPS $1.04 >BDX

7 lis 2024, 11:36 UTC

Earnings

Becton Dickinson Sees FY25 Rev $21.9B-$22.1B >BDX

7 lis 2024, 11:35 UTC

Earnings

Becton Dickinson Sees FY25 Adj EPS $14.25-Adj EPS $14.60 >BDX

7 lis 2024, 11:30 UTC

Earnings

Becton Dickinson 4Q EPS $1.45 >BDX

7 lis 2024, 11:30 UTC

Earnings

Becton Dickinson 4Q Adj EPS $3.81 >BDX

7 lis 2024, 11:30 UTC

Earnings

Becton Dickinson 4Q Rev $5.4B >BDX

7 lis 2024, 11:30 UTC

Earnings

Becton Dickinson 4Q Cont Ops EPS $1.45 >BDX

Peer Comparison

Price change

Becton Dickinson and Co Forecast

Price Target

By TipRanks

18.08% upside

12 Months Forecast

Average 201.8 USD  18.08%

High 255 USD

Low 172 USD

Based on 13 Wall Street analysts offering 12 month price targets forBecton Dickinson and Co - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

13 ratings

4

Buy

9

Hold

0

Sell

Technical Score

By Trading Central

167 / 206.99Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

91 / 380 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Becton Dickinson and Co

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.